When a scrappy team of scientists joined forces in the late 1990s, they sought to identify genetic mutations that could have an outsized impact on the treatment of human disease. At the time, that ...

Praxis Precision Medicines has received Breakthrough Therapy Designation (BTD) from the FDA for relutrigine, a sodium channel modulator intended for pediatric treatment of SCN2A and SCN8A ...

Bsense Bio Therapeutics Ltd. has nominated BSEN-760, a dual Kv7.2/3 and TRPV1 ion channel modulator, as a clinical candidate for the treatment of chronic pain.

LONDON, July 25, 2024 (GLOBE NEWSWIRE) -- Kaerus Bioscience Ltd. (www.kaerusbio.com), a clinical-stage biotechnology company focused on developing therapeutics for rare genetic syndromes of ...